Nanoscale artificial antigen presenting cells for T cell immunotherapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 119-129

  Perica, Karlo ^a   De León Medero, Andrés ^a   Durai, Malarvizhi ^a   Chiu, Yen Ling ^a   Bieler, Joan Glick ^a   Sibener, Leah ^a   Niemöller, Michaela ^b   Assenmacher, Mario ^b   Richter, Anne ^b   Edidin, Michael ^a   Oelke, Mathias ^a   Schneck, Jonathan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Artificial antigen presenting cell; Immunotherapy; Nanoparticle; T cell

Indexed keywords

ACTIVE IMMUNOTHERAPIES; ANTIGEN PRESENTING CELLS; ARTIFICIAL ANTIGEN; HUMAN PERIPHERAL BLOOD; IMMUNOTHERAPY; INHIBITION OF TUMOR GROWTH; INTERACTION PROPERTIES; PARAMAGNETIC PARTICLES;

ANTIGENS; BIOCOMPATIBILITY; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; DERMATOLOGY; DEXTRAN; IRON; MAMMALS; NANOCRYSTALS; NANOPARTICLES; NANOTECHNOLOGY; ONCOLOGY; SEMICONDUCTOR QUANTUM DOTS; T-CELLS; TUMORS;

CELLS;

AVIDIN; CD3 ANTIGEN; IRON DEXTRAN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NANOCRYSTAL; NANOPARTICLE; QUANTUM DOT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; ARTIFICIAL ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NANOANALYSIS; NONHUMAN; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ARTIFICIAL ANTIGEN PRESENTING CELL; IMMUNOTHERAPY; NANOPARTICLE; T CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; IRON-DEXTRAN COMPLEX; MELANOMA; MICE; NANOPARTICLES; QUANTUM DOTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84891018543     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.06.015     Document Type: Article

References (51)

1. Zhang N., Bevan M.J. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011, 35(2):161-168.
2. Ahlers J.D., Belyakov I.M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010, 115(9):1678-1689.
3. Wrzesinski C., Paulos C.M., Kaiser A., et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010, 33(1):1-7.
4. Mehrotra S, Al-Khami A a, Klarquist J, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. Journal of immunology (Baltimore, Md: 1950). 189(4), 1627-38 (2012).
5. Turtle C.J., Riddell S.R. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Current opinion in immunology 2011, 23(2):299-305.
6. Durai M., Krueger C., Ye Z., et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol, Immunother: CeII 2009, 58(2):209-220.
7. Oelke M., Schneck J.P. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunol Res 2010, 47:248-256.
8. Smith-Garvin J.E., Koretzky G.a., Jordan M.S. T cell activation. Ann Rev Immunol 2009, 27:591-619.
9. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31(13):3657-3666.
10. Decuzzi P., Godin B., Tanaka T., et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Rel 2010, 141(3):320-327.
11. Semete B., Booysen L., Lemmer Y., et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine: Nanotechnol Biol Med 2010, 6(5):662-671.
12. Sharma G., Valenta D.T., Altman Y., et al. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 2010, 147(3):408-412.
13. Champion J.a., Walker A., Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 2008, 25(8):1815-1821.
14. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38(5):1404-1413.
15. Mescher M.F. Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 1992, 149(7):2402-2405.
16. Steenblock E.R., Wrzesinski S.H., Flavell R. a, Fahmy TM. Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. Exp Opinion Biol Ther 2009, 9(4):451-464.
17. Balmert SC, Little SR. Biomimetic delivery with micro- and nanoparticles. Advanced materials (Deerfield Beach, Fla.). 24(28), 3757-78 (2012).
18. Hubbell J.a., Thomas S.N., Swartz M.a. Materials engineering for immunomodulation. Nature 2009, 462(7272):449-460.
19. Anikeeva N., Lebedeva T., Clapp A.R., et al. Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response. Proc Natl Acad Sci USA 2006, 103(45):16846-16851.
20. Boyle S., Kolin D.L., Bieler J.G., Schneck J.P., Wiseman P.W., Edidin M. Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen. Biophys J 2011, 101(11):L57-L59.
21. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Molec Ther: J Am Soc Gene Ther 2008, 16(4):765-772.
22. Kunzmann A., Andersson B., Thurnherr T., Krug H., Scheynius A., Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochimica et biophysica acta. 2010, 1810(3):361-373.
23. Dobrovolskaia M.a., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2(8):469-478.
24. Nune S.K., Gunda P., Majeti B.K., Thallapally P.K., Forrest M.L. Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev 2011, 63(10-11):876-885.
25. Motta I., Lone Y.C., Kourilsky P. In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density. European journal of immunology. 1998, 28(11):3685-3695.
26. Ge Q., Stone J.D., Thompson M.T., et al. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci USA 2002, 99(21):13729-13734.
27. Curtsinger J., Deeths M.J., Pease P., Mescher M.F. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. Journal of immunological methods. 1997, 209(1):47-57.
28. Hosken N, Shibuya K, Heath A, KM. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. The Journal of. 182(November), 20-22 (1995).
29. Alexander-Miller M.a., Leggatt G.R., Sarin A., Berzofsky J.a. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996, 184(2):485-492.
30. González P.a., Carreño L.J., Coombs D. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci U S A 2005, 102(13):4824-4829.
31. Bullock T.N.J., Mullins D.W., Engelhard V.H. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 2003, 170(4):1822-1829.
32. Mescher M.F., Popescu F.E., Gerner M., Hammerbeck C.D., Curtsinger J.M. Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Sem Cancer Biol 2007, 17(4):299-308.
33. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., Schneck J.P. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003, 9(5):619-625.
34. Altman J., Davis M. MHC-Peptide Tetramers to Visualize Antigenâ Specific T Cells. Curr Protocol Immunol 2003, 1-33.
35. Fifis T., Gamvrellis A., Crimeen-Irwin B., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173(5):3148-3154.
36. Cai S., Yang Q., Bagby T.R., Forrest M.L. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011, 63(10-11):901-908.
37. Lebowitz M.S., O'Herrin S.M. Hamad a R, et al. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol 1999, 192(2):175-184.
38. Moon J.J., Huang B., Irvine D.J. Engineering nano- and microparticles to tune immunity. Advanced materials (Deerfield Beach, Fla.) 2012, 24(28):3724-3746.
39. Dustin M.L. T-cell activation through immunological synapses and kinapses. Immunol Rev 2008, 221:77-89.
40. Chang J.T., Palanivel V.R., Kinjyo I., et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 2007, 315(5819):1687-1691.
41. Varma R., Campi G., Yokosuka T., Saito T., Dustin M.L. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 2006, 25:117-127.
42. Lillemeier B.F., Mörtelmaier M.a., Forstner M.B., Huppa J.B., Groves J.T., Davis M.M. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat Immunol 2010, 11(1):90-96.
43. Nel A.E., Mädler L., Velegol D., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8(7):543-557.
44. Fahmy T.M., Bieler J.G., Edidin M., Schneck J.P. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 2001, 14(2):135-143.
45. Kumar R., Ferez M., Swamy M., et al. Increased sensitivity of antigen-experienced T cells through the enrichment of oligomeric T cell receptor complexes. Immunity 2011, 35(3):375-387.
46. Reddy S.T., Van der Vlies A.J., Simeoni E., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25(10):1159-1164.
47. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41(00):189-207.
48. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007, 15(7-8):457-464.
49. Rabinovich G.a., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
50. Schneck JP, Slansky JE, O'Herrin SM, Greten TF. Monitoring antigen-specific T cells using MHC-Ig dimers. Current protocols in immunology / edited by John E. Coligan. [et al.]. Chapter 17, Unit 17.2 (2001).
51. Chiu Y.-L., Schneck J.P., Oelke M. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL. J Visualized Exp: JoVE. 2011, 50:1-5.